Minerva Neurosciences Inc (NAS:NERV)
$ 2.46 -0.02 (-0.81%) Market Cap: 17.21 Mil Enterprise Value: -17.48 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 37/100

Minerva Neurosciences, Inc. - Special Call Transcript

Mar 31, 2020 / 12:00PM GMT
Release Date Price: $48.16 (-5.94%)
Operator

Greetings, and welcome to the KOL call on roluperidone, a novel mechanism to treat the negative symptoms of schizophrenia, hosted by Minerva Neuroscience. (Operator Instructions) As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Mr. Bill Boni, Vice President of Investor Relations and Corporate Communications at Minerva Neurosciences. Please go ahead.

William B. Boni
Minerva Neurosciences, Inc. - VP of IR & Corporate Communications

Good morning, and welcome, everyone. On behalf of Minerva, thank you for attending this call, especially given the challenges we are all facing with the coronavirus. Today's speakers include Dr. Ofer Agid, Dr. Will Carpenter, Dr. John Kane and Dr. Stephen Marder.

The discussion will be moderated by Dr. Rémy Luthringer, Executive Chairman and CEO of Minerva. Also present from Minerva, is Dr. Michael Davidson, Chief Medical Officer.

Dr. Agid is Clinician Scientist and Psychiatrist in the Schizophrenia Program and Medical Head, Ambulatory Services and the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot